Legal & General Group Plc Raises Stock Holdings in Tempus AI, Inc. $TEM

Legal & General Group Plc boosted its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 14.3% in the fourth quarter, HoldingsChannel reports. The firm owned 558,262 shares of the company’s stock after purchasing an additional 70,020 shares during the period. Legal & General Group Plc’s holdings in Tempus AI were worth $32,965,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPL Wealth Management LLC purchased a new position in Tempus AI in the third quarter valued at about $26,000. Harvest Fund Management Co. Ltd purchased a new position in Tempus AI in the third quarter valued at about $38,000. Tsfg LLC lifted its holdings in Tempus AI by 1,515.2% during the 3rd quarter. Tsfg LLC now owns 533 shares of the company’s stock worth $43,000 after buying an additional 500 shares during the last quarter. Danske Bank A S bought a new position in Tempus AI during the 3rd quarter worth approximately $48,000. Finally, Sunbelt Securities Inc. bought a new position in Tempus AI during the 3rd quarter worth approximately $52,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Trading Down 1.6%

NASDAQ:TEM opened at $50.47 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The business’s 50 day moving average is $48.73 and its two-hundred day moving average is $58.19. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32. The company has a market cap of $9.06 billion, a PE ratio of -29.34 and a beta of 3.99.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business’s quarterly revenue was up 36.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.24) EPS. On average, analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current year.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus introduced Tempus Preview, a new application designed to deliver rapid, clinically significant insights before final diagnostic results are available, which could improve oncology workflows and strengthen the company’s AI-driven precision medicine offering. Article Title
• Positive Sentiment: The company launched the PRECISION Challenge, a national research program that opens its foundation-model work to a broader scientific community, potentially expanding Tempus’ data ecosystem, visibility, and long-term research partnerships. Article Title
• Positive Sentiment: Investors are also reacting to Tempus’ latest ASCO-related AI and multimodal foundation-model updates, which reinforce the company’s positioning as a leader in AI for oncology and may support sentiment around future growth. Article Title
• Neutral Sentiment: There was also unusual call-option activity and analyst/investor-day commentary, suggesting traders are positioning for bigger moves, but these signals are not yet clear enough to indicate a lasting directional catalyst. Article Title
• Negative Sentiment: CEO Eric Lefkofsky sold 166,250 shares in a pre-arranged 10b5-1 plan, which can still weigh on sentiment because insider selling often raises concerns about near-term upside, even when the sale is routine. Article Title
• Negative Sentiment: Tempus remains a high-volatility, unprofitable company with negative margins and a heavy debt load, so investors may be cautious despite the recent product momentum.

Analyst Upgrades and Downgrades

A number of research analysts have commented on TEM shares. Guggenheim reduced their target price on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, March 30th. HC Wainwright reduced their target price on Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Jefferies Financial Group started coverage on Tempus AI in a report on Monday, April 13th. They set an “underperform” rating and a $35.00 target price on the stock. TD Cowen increased their target price on Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Robert W. Baird started coverage on Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 target price on the stock. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $68.64.

Insider Buying and Selling at Tempus AI

In other news, CAO Ryan M. Bartolucci sold 4,116 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $181,392.12. Following the sale, the chief accounting officer directly owned 74,041 shares in the company, valued at approximately $3,262,986.87. This represents a 5.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 13,550 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $597,148.50. Following the sale, the chief executive officer owned 603,558 shares in the company, valued at $26,598,801.06. The trade was a 2.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 558,307 shares of company stock worth $26,599,589. Corporate insiders own 24.26% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.